AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Senior Female Scientist Works with High Tech Equipment in a Modern Laboratory. Her Colleagues are Working Beside Her.

Drug Development

Clinical Catch-Up: Updates for Achilles, Logic Bio, Roche and More

Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio’s pediatric methylmalonic acidemia study is back up and running and another look at Roche’s TIGIT flop.

May 13, 2022

7 min read

Mark Terry

Policy

AbbVie, Teva May Pay $5 Billion To Settle Opioid Lawsuit

AbbVie and Teva are reportedly ready to pay over $5 billion to quiet the over 3,500 opioid liability lawsuits filed against them over their painkillers.

May 12, 2022

2 min read

Vanessa Doctor, MS

Business

BMS and Merck Buy Big Into Amphista’s Protein Degradation Platform

Amphista Therapeutics forged two significant protein degradation partnerships with big pharma. Wednesday, the U.K.-based company announced partnerships with both Bristol Myers Squibb and Merck KGaA that have a combined value of more than $2 billion.

May 4, 2022

3 min read

Alex Keown

Business

Teva Holds off Huntington’s Competitor, Resolves Opioid Cases

Teva announced that it had reached a deal with Lupin over Lupin’s Abbreviated New Drug Application (ANDA) for generic deutetrabenazine - an upcoming competitor to Hungtington’s drug Austedo.

May 3, 2022

3 min read

Mark Terry

Aubrey Adams, AbbVie's U.S. Area Head for Therape

Drug Development

Following its North Star, AbbVie is Taking the Reigns in Migraine Treatment

Since its $63 billion acquisition of Allergan in 2019, AbbVie has become one of the leading companies developing therapies for migraine.

April 29, 2022

6 min read

Alex Keown

Courtesy of Smith Collection/Gado/Getty Images

Business

AbbVie Touts Another FDA Approval for Rinvoq, Posts Strong First Quarter

AbbVie is off to a strong start for 2022 driven by success from Skyrizi and Rinvoq, as well as the company’s neuroscience platform. Abbvie also won FDA approval for a new indication for Rinvoq.

April 29, 2022

4 min read

Alex Keown

AbbVie_© AbbVie Inc. All rights reserved.

Business

AbbVie Unites with Plexium to Leverage Protein Degraders Against Neurological Diseases

The alliance will pair AbbVie’s neuroscience capabilities with Plexium’s comprehensive TPD platform.

April 28, 2022

3 min read

Mark Terry

Drug Development

Roche MS Trial Woes Highlight Current Perils of Reliance on Eastern Europe

The war has shattered plans for a variety of clinical trials, but Roche is particularly concerned about fenebrutinib, a drug it is developing for multiple sclerosis (MS).

April 26, 2022

4 min read

Hannah Chudleigh